Research Output Journal of Public Health and Medicine 4(2):1-5, 2024

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2024/421500

Advances in Immune Biomarkers for Predicting Disease Outcomes and Therapeutic Responses

Muhindo Anitah

Department of Pharmacy Kampala International University Uganda

Email: anitah.muhindo@studwc.kiu.ac.ug

ABSTRACT

Immune biomarkers have become crucial for predicting disease outcomes and guiding therapeutic responses, particularly in conditions like cancer, autoimmune disorders, and infectious diseases. These biomarkers reflect the immune system's state activation, suppression, or modulation providing valuable insights into prognosis, treatment efficacy, and potential side effects. With advancements in molecular and cellular technologies such as high-throughput sequencing, single cell analysis, and bioinformatics, the identification and utilization of immune biomarkers have significantly evolved. This review focuses on the classification of immune biomarkers, including cellular, soluble, genetic, epigenetic, and metabolic biomarkers, and their mechanisms in predicting disease progression and therapeutic responses. We highlight the role of immune biomarkers in oncology, where they are essential for immunotherapy response prediction (e.g., PD-L1 expression, tumor mutational burden), and in autoimmune diseases, where they aid in monitoring disease activity and response to treatments like biologics. Moreover, emerging techniques such as single-cell profiling and multiplex assays offer new opportunities for personalized medicine. However, challenges like immune system heterogeneity, dynamic biomarker levels, and assay standardization hinder their clinical application. As research advances, immune biomarkers will increasingly support precision medicine, offering personalized therapies that improve patient outcomes. This review discusses these advances, their clinical implications, and the challenges in integrating immune biomarkers into routine practice, while emphasizing the future potential for further breakthroughs.

Keywords: Immune biomarkers, disease outcomes, immunotherapy, autoimmune diseases, personalized medicine, therapeutic response

INTRODUCTION

Immune biomarkers have emerged as essential tools in predicting disease outcomes and guiding therapeutic strategies, particularly in conditions where the immune system plays a pivotal role, such as cancer, autoimmune diseases, and infectious diseases [1]. These biomarkers are measurable indicators of immune activity, providing crucial insights into the immune system's status—whether it is activated, suppressed, or dysregulated. They offer the potential to assess disease severity, predict treatment responses, and monitor disease progression over time [2]. In oncology, immune biomarkers are fundamental in predicting patient responses to immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1, PD-L1, and CTLA-4), which have transformed cancer treatment [3]. These biomarkers help identify which patients are likely to benefit from these therapies, thereby optimizing treatment decisions. In autoimmune diseases, biomarkers of immune activation or suppression, like regulatory T cell (Treg) function and cytokine levels, are critical in assessing disease activity and tailoring immunosuppressive therapies [4]. Moreover, in infectious diseases, biomarkers that reflect host immune responses help evaluate the effectiveness of vaccines or antiviral therapies. Recent advances in molecular and cellular technologies—such as high-throughput sequencing, single-cell RNA analysis, and bioinformatics—have significantly enhanced the

discovery and application of immune biomarkers [5]. These developments have expanded the scope of biomarkers to include genetic, epigenetic, and metabolic markers, offering new opportunities for precision medicine. This review will explore the types of immune biomarkers, their mechanisms, and their implications for disease prognosis and treatment responses, while also addressing the challenges of integrating them into clinical practice.

Types of Immune Biomarkers

Immune biomarkers are diverse and can be classified into various categories based on their origin and function. These include cellular biomarkers, soluble biomarkers, genetic and epigenetic biomarkers, and metabolic biomarkers.

Cellular Biomarkers

Cellular biomarkers include immune cell populations that reflect the immune system's status in different disease contexts. For example, in cancer immunotherapy, tumor-infiltrating lymphocytes (TILs) and the expression of checkpoint molecules like PD-1 and CTLA-4 on T cells are critical for predicting therapeutic responses [6]. In autoimmune diseases, the ratio of regulatory T cells (Tregs) to effector T cells (Teffs) can indicate disease activity and the likelihood of a response to immunosuppressive treatments. Single-cell RNA sequencing and flow cytometry have advanced the identification and characterization of specific immune cell subsets that are relevant to disease prognosis and treatment outcomes [7]. These techniques allow for a more detailed analysis of immune cell heterogeneity within tissues, providing a better understanding of how the immune system is altered in different diseases.

Soluble Biomarkers

Soluble biomarkers refer to proteins, cytokines, and chemokines found in bodily fluids, such as blood, serum, or cerebrospinal fluid, which can reflect immune activity. In cancer, elevated levels of soluble PD-L1 have been associated with poor prognosis and resistance to checkpoint blockade therapies [8]. Similarly, cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are markers of systemic inflammation and can predict disease severity in autoimmune diseases like rheumatoid arthritis and lupus [9]. Advances in multiplex assays, such as Luminex or ELISA-based platforms, have allowed for the simultaneous measurement of multiple cytokines and proteins, providing a broader picture of the immune landscape in a patient [10]. These platforms are particularly useful for monitoring immune responses to treatments and identifying changes in immune activity that correlate with therapeutic efficacy.

Genetic and Epigenetic Biomarkers

Genetic variations and epigenetic modifications that affect immune function are also key biomarkers for predicting disease outcomes. In cancer, mutations in genes like TP53 and alterations in the tumor mutational burden (TMB) are associated with responses to immunotherapies, particularly immune checkpoint inhibitors [11]. In autoimmune diseases, certain HLA alleles have been linked to disease susceptibility and severity. For instance, HLA-DRB11501 is associated with an increased risk of developing multiple sclerosis [12]. Epigenetic changes, such as DNA methylation patterns in immune cells, can also serve as biomarkers. These modifications can influence gene expression and, therefore, the function of immune cells. In cancer, DNA methylation patterns in circulating tumor DNA (ctDNA) are emerging as important biomarkers for detecting minimal residual disease and predicting responses to therapy [13].

Metabolic Biomarkers

The metabolic state of immune cells can profoundly influence their function and has been identified as a potential biomarker for disease outcomes. Immune cells undergo metabolic reprogramming in response to activation, which can be measured through metabolites such as lactate, glucose, and fatty acids [14]. For example, in cancer, the metabolic shift toward glycolysis (the Warburg effect) in T cells can predict their ability to sustain an anti-tumor response [15]. In autoimmune diseases, altered metabolism in Tregs has been linked to their dysfunction and the loss of immune tolerance. Mass spectrometry and metabolomics platforms are enabling the detailed profiling of immune cell metabolism, providing new insights into how metabolic pathways influence immune responses and therapeutic outcomes [16].

ROLE OF IMMUNE BIOMARKERS IN DISEASE OUTCOMES

Cancer Immunotherapy

The advent of immune checkpoint inhibitors has revolutionized cancer treatment, but not all patients respond to these therapies. Predictive immune biomarkers, such as PD-L1 expression and TMB, are critical for identifying patients who are likely to benefit from these treatments [17]. PD-L1 expression on tumor cells and immune cells in the tumor microenvironment (TME) has been correlated with better responses to PD-1/PD-L1 inhibitors, while a high TMB is associated with a higher likelihood of generating neoantigens that can be recognized by T

cells, leading to improved responses [18,19]. Other emerging biomarkers in cancer immunotherapy include the presence of specific immune cell subsets in the TME, such as TILs, as well as immune gene signatures derived from RNA expression profiling [20].

Autoimmune Diseases

In autoimmune diseases, immune biomarkers help predict disease activity, progression, and therapeutic responses. For instance, anti-citrullinated protein antibodies (ACPAs) are biomarkers for rheumatoid arthritis and are associated with more severe disease and increased risk of joint damage [21]. Similarly, levels of certain cytokines, such as IL-6 and TNF-α, are elevated during disease flares and can be used to monitor response to biologic therapies that target these pathways [22]. Biomarkers of regulatory T cell function are also being explored as predictors of treatment response in autoimmune diseases. Low levels of Tregs or impaired Treg function are associated with poor outcomes and resistance to therapies like methotrexate or TNF inhibitors [23].

Challenges and Future Directions

Despite the significant advancements in immune biomarkers, several challenges persist in their clinical application. One of the primary hurdles is the complexity and heterogeneity of the immune system. Immune responses vary widely across individuals, diseases, and therapeutic contexts, making it difficult to identify a single biomarker that can reliably predict outcomes across different conditions [24]. Moreover, immune biomarkers are dynamic, with levels that can fluctuate based on disease progression, treatment interventions, or even time of day, adding another layer of complexity to their interpretation. The integration of immune biomarkers into clinical practice presents further challenges. Standardizing assays across laboratories and healthcare systems is critical to ensure consistency and reliability. Moreover, the validation of biomarkers in large, diverse patient cohorts is necessary to confirm their utility and accuracy across different populations and disease states [25]. Developing robust, reproducible tests that can be easily adopted in clinical settings is also essential to translating biomarker discoveries into routine use. Looking ahead, advances in artificial intelligence (AI) and machine learning (ML) are expected to play pivotal roles in overcoming these challenges. AI and ML algorithms can analyze vast and complex biomarker datasets, identify patterns that are not discernible through traditional statistical methods, and uncover novel biomarker signatures that can predict disease outcomes and therapeutic responses with greater accuracy [26]. These technologies hold the potential to personalize treatment decisions, improve diagnostic precision, and optimize patient outcomes, marking a significant step forward in the use of immune biomarkers in precision medicine.

CONCLUSION

The development of immune biomarkers has greatly enhanced our ability to predict disease outcomes and tailor therapies to individual patients. Advances in technologies such as genomics, proteomics, and metabolomics have expanded the range of potential biomarkers and improved our understanding of the immune landscape in various diseases. While challenges remain, the integration of immune biomarkers into clinical practice holds great promise for advancing precision medicine and improving patient outcomes across a range of immune-related diseases. Continued research and validation efforts are critical to fully realize the potential of immune biomarkers in predicting disease outcomes and therapeutic responses.

REFERENCES

1. Trzeciak A, Pietropaoli AP, Kim M. Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis. Immune Netw. 2020; 20(3):e23. doi: 10.4110/in.2020.20.e23.
2. Selvaskandan H, Shi S, Twaij S, Cheung CK, Barratt J. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Frontiers in immunology. 2020; 11:572754.
3. Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative analysis of predictive biomarkers for PD-1/PD-L1 inhibitors in cancers: developments and challenges. Cancers. 2021; 14(1):109.
4. Honing DY, Luiten RM, Matos TR. Regulatory T Cell Dysfunction in Autoimmune Diseases. International Journal of Molecular Sciences. 2024; 25(13):7171.
5. Alum, E. U. Career Advancement towards Nascent Technologies: RNA in Focus. IDOSR JOURNAL OF SCIENTIFIC RESEARCH. 9(2):49-53. (2024). https://doi.org/10.59298/IDOSRJSR/2024/9.2.4953.100
6. Presti D, Dall'Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. Critical Reviews in Oncology/Hematology. 2022; 177:103773.
7. Chen H, Ye F, Guo G. Revolutionizing immunology with single-cell RNA sequencing. Cellular & molecular immunology. 2019; 16(3):242-9.

8. Oh SY, Kim S, Keam B, Kim TM, Kim DW, Heo DS. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Scientific reports. 2021; 11(1):19712.
9. Ibiam, U. A., Alum, E. U., Orji, O. U., Aja, P. M., Ezeani, N. N., Ugwu, O. P. C. and Ekpono, E. U. Anti-Inflammatory Effects of *Buchholzia coriacea* Ethanol Leaf-Extract and Fractions in Freund's Adjuvant-Induced Rheumatoid Arthritis Albino Rats. *Indo American Journal of Pharmaceutical Sciences (IAJPS)*. 2018; 5 (7): 6341-6357. https://doi.org/10.5281/zenodo.1311167.
10. Deng J, Wang L, Ni J, Beretov J, Wasinger V, Wu D, Duan W, Graham P, Li Y. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Rev Proteomics. 2016; 13(10):905-915. doi: 10.1080/14789450.2016.1233065.
11. Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, Pluvy J, Gounant V, Khalil A, Namour C, Brosseau S. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung cancer. 2019; 132:65-71.
12. Hussain MS, Gupta G, Samuel VP, Almalki WH, Kazmi I, Alzarea SI, Saleem S, Khan R, Altwaijry N, Patel S, Patel A. Immunopathology of herpes simplex virus-associated neuroinflammation: Unveiling the mysteries. Reviews in Medical Virology. 2024; 34(1): e2491.
13. Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, Dai W, Wang Y, Luo W, Wang R, Xu Y. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA oncology. 2023; 9(6):770-8.
14. Mohammadnezhad L, Shekarkar Azgomi M, La Manna MP, Sireci G, Rizzo C, Badami GD, Tamburini B, Dieli F, Guggino G, Caccamo N. Metabolic reprogramming of innate immune cells as a possible source of new therapeutic approaches in autoimmunity. Cells. 2022; 11(10):1663.
15. Dabi YT, Andualem H, Degechisa ST, Gizaw ST. Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response. Biologics. 2022 May 9; 16:35-45. doi: 10.2147/BTT.S365490. PMID: 35592358; PMCID: PMC9113448.
16. Diray-Arce J, Conti MG, Petrova B, Kanarek N, Angelidou A, Levy O. Integrative metabolomics to identify molecular signatures of responses to vaccines and infections. Metabolites. 2020; 10(12):492.
17. Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021; 13(3):558.
18. Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Niaragh FJ, Safaei S, Asadi M, Baradaran B. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sciences. 2020; 259:118297.
19. Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer gene therapy. 2020; 27(12):841-53.
20. Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021; 10(2):223.
21. Trier NH, Houen G. Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis. Expert Review of Molecular Diagnostics. 2023; 23(10):895-911.
22. Zhang C. Flare-up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review). Biomed Rep. 2021; 14(1):16. doi: 10.3892/br.2020.1392.
23. Guo H, Li L, Liu B, Lu P, Cao Z, Ji X, Ouyang G, Nie Z, Lyu A, Lu C. Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis. International Immunopharmacology. 2023; 122:110655.
24. Laigle L, Chadli L, Moingeon P. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Review of Clinical Immunology. 2023;19(3):305-14.
25. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, Burczynski ME, Crean C, Edwards R, Gaudilliere B, Hergenroeder GW. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nature Reviews Neurology. 2020; 16(7):381-400.
26. Raikar GV, Raikar AS, Somnache SN. Advancements in artificial intelligence and machine learning in revolutionising biomarker discovery. Brazilian Journal of Pharmaceutical Sciences. 2023; 59:e23146.

CITE AS: Muhindo Anitah (2024). Advances in Immune Biomarkers for Predicting Disease Outcomes and Therapeutic Responses. Research Output Journal of Public Health and Medicine 4(2):1-5. https://doi.org/10.59298/ROJPHM/2024/421500